Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.

Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.

CYSTOID MACULAR EDEMA

Intravitreal injection of Ranibizumab as treatment for acute pseudophakic cystoid macular edema. Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.

Ranibizumab,

Intravitreal injection of Triamcinolone acetonide as treatment for acute pseudophakic cystoid macular edema. Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.

Triamcinolone acetonide

Soll Eye

Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide

To assess the safety of intravitreal R and T for the treatment of acute pseudophakic cystoid macular edema by evaluating:
Incidence and severity of ocular adverse events, as identified by eye examination
Incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs

Mean change in spectral domain OCT CMT from baseline (microns)

Mean change in ETDRS letters from baseline (letters)

Proportion of patients with 3 line or better ETDRS letter improvement (%)

Time to 3 line ETDRS letter improvement (days)

Genentech, Inc.

Pediatric Glaucoma

FP7 Ahmed Glaucoma Drainage Implant

FP8 Glaucoma Drainage Implant

Federal University of São Paulo - Ophthalmology Department

Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma

Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma: a Randomized Clinical Trial.

The primary endpoint is to evaluate the position of the drainage implant plate and if the plate is positioned at a distance ≥ 8 mm from the corneal limbus after 1 year of surgery, considered successful. If the plate is positioned at a distance <8 mm from the corneal limbus, we have a failure.

We will use as a criterion of success an IOP ≤ 21 mm Hg and> 5 mmHg and a 30% reduction of preoperative IOP. If the patient meets these criteria, without the use of eyedrop, classified as complete success. If the use of eyedrop is necessary to meet the criteria, a qualified success will be defined.
For failure criterion is assumed: IOP ≤ 5 mmHg or > 21 mm Hg, even with the use of eye drops, need for further surgery, and / or loss of light perception.

vitreous hemorrhage/nàusea

Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide

Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma

La base de dades d’herbes medicinals més completa avalada per la ciència